Keros Therapeutics, Inc. (KROS)

Market Cap	439.91M
Revenue (ttm)	651,000
Net Income (ttm)	-181.57M
Shares Out	40.51M
EPS (ttm)	-5.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,961,551
Open	11.00
Previous Close	10.52
Day's Range	10.74 - 11.63
52-Week Range	9.78 - 73.00
Beta	1.43
Analysts	Buy
Price Target	45.33 (+317.4%)
Earnings Date	Feb 26, 2025

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 8, 2020
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: KROS
• Website: https://www.kerostx.com

Analyst Forecast

According to 11 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is $45.33, which is an increase of 317.40% from the latest price.

Price Target

$45.33

(317.40% upside)

Analyst Consensus: Buy